SGLT2 inhibitors may reduce rehospitalization in diuretic-resistant heart failure with good renal safety, while nephron-segment add-ons improve decongestion but need AKI/electrolyte monitoring.
Do SGLT2 inhibitors or nephron-segment add-ons improve outcomes in patients with heart failure and diuretic resistance?
In heart failure with diuretic resistance, SGLT2 inhibitors may reduce rehospitalization while nephron-segment add-ons improve short-term decongestion but require careful safety monitoring.
Absolute Event Rate: 0% vs 0%
In HF with diuretic resistance, sodium-glucose cotransporter 2 inhibitors may lower rehospitalization with a favorable renal profile, whereas nephron-segment add-ons enhance short-term decongestion but warrant AKI/electrolyte monitoring; rankings are exploratory, and choices should emphasize absolute effects and 95% CIs.
Lima et al. (Mon,) reported a other. SGLT2 inhibitors may reduce rehospitalization in diuretic-resistant heart failure with good renal safety, while nephron-segment add-ons improve decongestion but need AKI/electrolyte monitoring.